¿Û¿Û´«Ã½

This transformed FTSE 100 insurer still offers a high yield

A significant acquisition is being integrated and will be good news for shareholder returns

An oversold US healthcare giant that’s now a bargain

The medical equipment manufacturer has been ailing, but its condition should stabilise

A French pharma group rediscovering its joie de vivre

The company’s turnaround progress is slow but will reward patient investors

This FTSE 100 distributor can’t stop delivering upgrades

It offers unusually high returns and a re-rating that has further to run

This retailer’s recovery is complete – now it’s time to grow

Shares in the FTSE 250 company are up 60 per cent, and now management can focus on its strong strategy

A housebuilder that’s firmly ahead of its rivals

House prices where this FTSE 100 developer focuses are rising faster than the average

Boost your income with this diversified and discounted trust

The manager strives to grow total returns by combining a solid yield with earnings growth

This FTSE 250 player offers growth at a good price

The investment platform is laying the foundations for a strong recovery

A rare opportunity to buy a quality stock at a discount

The market is fretting about AI, but this FTSE 100 giant’s competitive moat remains robust

Time to stop ignoring this cash-backed biotech

The Aim-traded stock offers investors the chance to play the big themes in drug development